Stock Research: Towa Pharmaceutical

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Towa Pharmaceutical

TSE:4553 JP3623150004
75
  • Value
    53
  • Growth
    22
  • Safety
    Safety
    100
  • Combined
    70
  • Sentiment
    72
  • 360° View
    360° View
    75
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Towa Pharmaceutical Co Ltd manufactures and sells pharmaceuticals, primarily generic drugs, and is also involved in the research and outsourced manufacture of active pharmaceutical ingredients and soft capsules, as well as the planning, development, and contract manufacturing of health foods, general foods, and miscellaneous goods. The company is based in Japan. In the last fiscal year, the company had a market cap of $1092 millions, profits of $632 millions, revenue of $1731 millions, and 4788 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 75 (better than 75% compared with alternatives) for 2025, overall professional sentiment and financial characteristics for the stock Towa Pharmaceutical are very positive. The 360° View is based on consolidating four consolidated indicators, with half of the indicators below and half above average for Towa Pharmaceutical. The consolidated Value Rank has an attractive rank of 100, which means that the share price of Towa Pharmaceutical is on the lower side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 100% of alternative stocks in the same industry. The company is also safely financed with a Safety rank of 53. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 72. But the consolidated Growth Rank has a low rank of 22, which means that the company is below average in terms of growth and momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. 78 of its competitors have better growth. ...read more

more
Index
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 2-Oct-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
100 96 100 99
Growth
22 26 63 79
Safety
Safety
53 47 37 63
Sentiment
72 68 45 37
360° View
360° View
75 72 73 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
62 60 63 46
Opinions Change
50 50 79 50
Pro Holdings
n/a 66 48 53
Market Pulse
64 52 11 28
Sentiment
72 68 45 37
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
100 96 100 99
Growth
22 26 63 79
Safety Safety
53 47 37 63
Combined
70 67 88 98
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
100 97 90 100
Price vs. Earnings (P/E)
97 97 97 100
Price vs. Book (P/B)
93 90 89 82
Dividend Yield
72 58 76 81
Value
100 96 100 99
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
50 45 46 72
Profit Growth
30 30 96 55
Capital Growth
10 4 7 5
Stock Returns
60 62 63 100
Growth
22 26 63 79
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
5 3 1 10
Refinancing
98 98 99 87
Liquidity
45 37 32 70
Safety Safety
53 47 37 63

Similar Stocks

Discover high‑ranked alternatives to Towa Pharmaceutical and broaden your portfolio horizons.

Japan Airlines

TSE:9201
Country: Japan
Industry: Airlines
Size: X-Large
Full Stock Analysis

Daiwabo Holdings

TSE:3107
Country: Japan
Industry: Technology Distributors
Size: Medium
Full Stock Analysis

Alfresa Holdings

TSE:2784
Country: Japan
Industry: Health Care Distributors
Size: Large
Full Stock Analysis

Hisamitsu Pharmaceutical

TSE:4530
Country: Japan
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.